
Erratum: Biopharmaceutical benchmarks—2003

Gary Walsh

Nat. Biotechnol. 21, 865–870 (2003)

In Box 3 of the article on p. 868, it was stated that the Dutch company Pharming NV went bankrupt in 2001. In that year the company did go into receivership and its subsidiary (Pharming intellectual property BV) was declared bankrupt. We fully accept, however, that Pharming itself did not go bankrupt. Pharming continues to trade successfully and currently has a number of products in both preclinical and clinical trials. *NBT* regrets the error.

Corrigendum: Phosphospecific proteolysis for mapping sites of protein phosphorylation

Zachary A Knight, Birgit Schilling, Richard H Row, Denise M Kenski, Bradford W Gibson & Kevan M Shokat

Nat. Biotechnol. 21, 1047–1054 (2003)

The above report failed to cite a relevant paper by Gary Hathaway and colleagues at the California Institute of Technology (Pasadena, CA, USA) entitled “Identification of Phosphorylated and Glycosylated Sites in Peptides by Chemically Targeted Proteolysis,” which was published in the December 2002 issue of the *Journal of Biomolecular Techniques* (13, 228–237, 2002; <http://jbt.abrf.org/cgi/reprint/13/4/228>) while the *Nature Biotechnology* paper was in review. The two papers describe essentially the same chemistry aimed at producing aminoethylcysteine in place of phosphoserine or phosphothreonine residues for the purpose of generating proteolytic cleavage at sites of phosphorylation.